News & Articles

Genera Research presented the latest progress in the preclinical and clinical development of OSTEOGROW-C at the 20th Tissue Engineering and Regenerative Medicine International Society (TERMIS) conference, held in Palma de Mallorca from April 20–24, 2026. TERMIS is one of the leading global platforms in the field of tissue engineering and regenerative medicine, bringing together scientists, clinicians, and industry experts from around the world to share advances and foster collaboration. As part of the scientific programme, Genera Research contributed to the session “Advanced biomaterials for bone regeneration”, chaired by Prof. Slobodan Vukičević (Zagreb, Croatia), Prof. Reinhard Windhager (Vienna, Austria), and Dr. Flavia Medeiros Savi (Melbourne, Australia). During the 90-minute session, key milestones in the development of OSTEOGROW technology were presented: Prof. Reinhard Windhager provided an overview of previous clinical trials using different OSTEOGROW formulations. Dr. Nikola Štoković and Dr. Natalia Ivanjko presented preclinical in vitro and in vivo studies on the OSTEOGROW-C formulation. Prof. Slobodan Vukičević concluded the session with a comprehensive overview of the discovery and development of OSTEOGROW, including the regulatory pathway toward a Phase III clinical study. The session also featured presentations from researchers across Europe, including contributions from Finland, Austria, and Italy, highlighting the latest developments in biomaterials for bone regeneration. The conference gathered more than 2,000 participants from across the globe, providing an important platform for scientific exchange and collaboration. The OSTEOGROW-C presentations attracted strong interest from the audience, particularly in the context of its potential as a first-in-class product following Phase III global clinical testing in patients with long bone fracture nonunions. Participation in TERMIS 2026 further reinforces Genera Research’s position at the forefront of regenerative medicine and orthobiologic innovation.

Genera Research Ltd. is participating in the MedTech Innovator Radar Forum 2026, held from April 7–9 in Manhattan Beach, California. The Radar Forum represents a central part of the MedTech Innovator evaluation process, where selected companies present their technologies through live pitch sessions and engage directly with investors, industry leaders, and clinical experts. Insights from these sessions contribute to the final selection of companies for the MedTech Innovator accelerator. MedTech Innovator is recognized as the world’s largest accelerator for medical device, digital health, and diagnostic companies, focused on advancing innovations that improve patient outcomes and transform healthcare globally. Participation in the Radar Forum places Genera Research among a select group of companies developing high-impact medical technologies. On the first day of the event, Genera Research presented its technology, OSTEOGROW-C, in front of four panels of expert judges. The sessions included direct discussions and feedback from investors, strategics, and key decision-makers in the medtech field. The Forum continues over the following days with additional meetings and networking opportunities, providing a valuable platform for further discussions and potential collaborations.

Croatian Science Foundation (HRZZ), Croatian Agency for SMEs, Innovation and Investment (HAMAG-BICRO), and the Ministry of Science, Education and Youth (MZOM) organised the National Info Day of the Horizon Europe Programme - European Innovation Council (EIC). At the EIC Info Day held in Zagreb on 18 February 2026, Dora Adanić took part as a speaker in a discussion focused on the EIC Accelerator programme and its highly competitive evaluation process. During the session, she shared practical insights on what makes a proposal stand out, the importance of building a strong team alongside breakthrough technology, and how companies should prepare 6–12 months ahead of submission. She also addressed key topics such as risk management, scale-up strategy, competition, and the value of coaching and external feedback when developing a successful application. The discussion concluded with concrete advice for future applicants aiming to secure EIC Accelerator support.

From 19–21 November 2025, representatives of Genera Research Ltd. visited the Cleveland Clinic Foundation in Cleveland, Ohio, following an invitation from the Cleveland Clinic Innovations team. Cleveland Clinic is one of the world’s leading academic medical centers, internationally recognized for excellence in clinical care, biomedical research, innovation, and orthopaedic medicine. The visit provided an important opportunity to present OSTEOGROW-C, Genera’s Phase III biological drug candidate for the treatment of bone fracture non-unions, to the Department of Orthopaedics and Traumatology and to the Innovation Department. Discussions focused on Cleveland Clinic’s potential participation in the Phase III clinical trial and on defining future collaboration models. A dedicated lecture was delivered at the Musculoskeletal Research Center, where more than 50 orthopaedic surgeons and traumatologists attended the presentation online, demonstrating strong professional interest in the therapy. The visit marked a significant step in Genera’s US clinical expansion strategy and reinforced the importance of international partnerships in advancing innovative regenerative therapies.

OSTEOproDENT—Research and Development of an Advanced Formulation for Alveolar Ridge Augmentation—is a collaborative initiative led by Sartorius Croatia – Libra Elektronik d.o.o. in partnership with Genera Research, the University of Zagreb School of Medicine, and Dental Office Bekavac. The project kicked off on January 13, 2025, and is projected to run through January 12, 2028, with a total budget of €4.67 million (€2.7 million in EU co‑financing)

Genera Research Ltd., a Croatian biotech company and pioneer in bone regeneration, is growing its expert team to support the implementation of our OSTEOforUNION and OSTEOproDENT projects — a groundbreaking initiative focused on the clinical-grade production of rhBMP6, the active substance in our novel biologic drug OSTEOGROW, designed to regenerate bone tissue.

We seek 2 Biotechnology Engineers ready to work hands-on in GMP manufacturing biological substances using CHO cell cultures, Biostat RM bioreactors, MyCap systems, and FPLC/HPLC chromatography techniques.

We actively recruit highly motivated professionals across multiple disciplines as we scale up GMP manufacturing, regulatory operations, clinical trials, and commercial readiness. We seek individuals who are not only technically qualified but also deeply committed to innovation, compliance, and improving patients’ lives through cutting-edge science.

Genera Research Ltd. participated in the BIO International Convention 2025, the world’s leading biotechnology partnering event bringing together global pharmaceutical companies, investors, and innovators in life sciences. At BIO 2025, Genera Research Ltd. presented OSTEOGROW-C, its late-stage biological drug candidate for the treatment of bone fracture non-unions (FNU), currently in Phase III clinical development (TRL 8). OSTEOGROW-C is a first-in-class regenerative therapy based on recombinant human BMP-6 delivered in an autologous blood coagulum with a compression-resistant ceramic matrix, designed to stimulate targeted bone regeneration without the need for autologous bone graft harvesting. With more than 6 million fracture non-union cases globally each year, including approximately 120,000 annually in the United States, OSTEOGROW-C addresses a significant unmet medical need in orthopaedics and trauma care. The therapy aims to redefine the standard of care by offering a biologically driven, patient-specific solution that reduces surgical burden and associated complications. BIO 2025 provided a strategic platform to showcase clinical results, engage with US-based pharma and orthopaedic partners, and advance discussions on licensing, investment, and future commercialisation in the United States.

Prof. Vukičević, CEO of Genera Research Ltd., delivered a lecture titled “BMP-6: Is This the Future for Bone Guided Regeneration?” at the E.S.T.R.O.T. conference, a leading international meeting dedicated to advances in orthopaedics, bone biology, and regenerative medicine. E.S.T.R.O.T. gathers prominent researchers, clinicians, and industry leaders to present cutting-edge scientific findings and discuss emerging therapeutic strategies in musculoskeletal medicine. The conference serves as an important platform for translating scientific discoveries into clinical innovation. In his presentation, Prof. Vukičević addressed the scientific foundation and clinical potential of Bone Morphogenetic Protein-6 (BMP-6) in guided bone regeneration. By highlighting its translational relevance and future therapeutic applications, the lecture underscored Genera Research’s ongoing commitment to advancing breakthrough solutions in bone repair and regenerative medicine.

Genera Research Ltd. participated in the TERMIS EU 2025 conference, a leading European event in the field of tissue engineering and regenerative medicine, held in Freiburg, Germany. The conference brought together researchers, clinicians, and industry experts to discuss the latest scientific advances and technological innovations shaping the future of regenerative medicine. By attending TERMIS EU 2025, Genera Research Ltd. strengthened its international collaborations, exchanged knowledge with key stakeholders, and followed the latest developments relevant to its ongoing research and innovation activities.

Genera Research Ltd. participated in the 14th International Bone Morphogenetic Protein (BMP) Conference, held at the University of Pennsylvania in Philadelphia, bringing together leading scientists to discuss the latest advances in BMP research and regenerative medicine. Academician Slobodan Vukičević, CEO of Genera Research, delivered an invited lecture on the first Croatian bone regeneration therapy and the OSTEOforUNION project, which received funding in 2024 from the European Innovation Council (EIC) Accelerator. This award marks Genera Research Ltd. as the first Croatian company supported by the EIC Accelerator for Phase II/III clinical trials in patients with long bone non-union. The conference also represented Genera’s first appearance as a sponsor of a major international scientific meeting, with project collaborators presenting additional data on Osteogrow across several program sessions.

The Croatian Science Foundation (HRZZ), the Croatian Agency for SMEs, Innovation and Investment (HAMAG-BICRO), and the Ministry of Science, Education and Youth (MZOM) organized the National Information Day dedicated to the Horizon Europe European Innovation Council (EIC) programme. Held on 20 February 2025, the event aimed to inform and encourage new applicants from the academic, technological, and innovation sectors to prepare and submit project proposals to upcoming EIC calls. Participants were also introduced to the EIC Work Programme for 2025. Dora Adanić, COO of Genera Research, presented the OSTEOforUNION project as a successful example of an initiative supported by the EIC Investment Fund.

The EIC Summit 2025, held on April 2–3, 2025, in Brussels, Belgium, took place at Tour & Taxis, a historic and modernized event venue known for hosting high-profile European innovation gatherings. The Summit brought together a dynamic community of innovators, investors, policymakers, and industry leaders funded or engaged through the European Innovation Council (EIC). This high-level platform showcased breakthrough technologies supported by the EIC and facilitated strategic collaborations across sectors. The event featured keynote presentations, expert panels, thematic workshops, pitch sessions, and one-on-one matchmaking meetings. Key topics included deep tech investment trends, scaling scientific innovation, commercialization of advanced therapeutics, and public-private partnership opportunities. As a funded project under the EIC Accelerator, Genera Research Ltd. participated in presenting its OSTEOforUNION project and Osteogrow platform, and connected with potential venture capital firms, strategic investors, and EU-based co-development partners. The format enabled meaningful exchanges with stakeholders interested in regenerative medicine, biologics, and clinical-stage innovation, laying the groundwork for follow-up discussions and potential partnerships.

Genera Research is proud to announce a significant milestone in the world of regenerative medicine with the successful recruitment of the first patient in Phase II of a clinical study. This study is focused on testing the efficacy, safety, and tolerability of Osteogrow (recombinant human bone morphogenetic protein 6 in autologous blood coagulum) in alveolar ridge regeneration following tooth extraction. The clinical site for this groundbreaking study is the prestigious Stomatology Faculty of the University of Zagreb.

In medical breakthroughs, the OSTEOproSPINE project, with Genera Research as a clinical trials sponsor and a consortium partner, has been spotlighted by CORDIS in the ‘Results in Brief’ section of the European Commission’s website. This recognition underscores the significant strides in developing Osteogrow, a novel treatment promising to revolutionize bone regeneration and relieve millions suffering from chronic lumbar back pain in the EU. The phase II clinical trial, backed by Genera Research, has shown that Osteogrow can effectively stabilize the lumbar spine and mitigate pain recurrence. Such innovative advancements exemplify our commitment to pioneering drug discovery and development. As we progress with the final Phase III clinical trials, we are inspired by the CORDIS selection to continue our mission of delivering life-changing treatments to the market. The anticipated introduction of Osteogrow-C in the EU market by 2028 is set to substantially impact patients' quality of life, making a significant milestone for Genera Research and the medical community at large​​.

The Symposium on Regenerative Medicine - New Platforms and Potentials, hosted by the Center of Excellence for Reproductive and Regenerative Medicine (CERRM) – Subunit for Regenerative Medicine, took place at the Amadria Park Hotel Royal in Opatija from October 23-25, 2023. This event was a collaborative effort, with Genera Research as a partner, featuring guest lecturers from its esteemed team.

On 25.10.2022 Genera Research COO Dora Adanić had the privilege to be a guest lecturer at Libertas International University in Zagreb on the Technology and Innovation Management course under the guidance of doc. Dr.sc. Helena Šlogar. The lecture topic was "Development and clinical testing of Osteogrow, the first Croatian drug for global use".

Genera Research was one of the sponsors of the 13th International BMP Conference 2022 held in Dubrovnik, Croatia, from the 8th to the 12th of October.

On June 19th, 2018 at the “Let the Stars Shine” exhibition in the European Parliament in Brussels project OSTEOGROW, coordinated by the University of Zagreb School of Medicine, was presented as one of five most significant Croatian projects financed by the European Union.

After the common cold, it is the second most common medical condition, and in more severe cases, surgery is usually perfomed.

The University of Zagreb School of Medicine is the head of the OsteoProSpine project, in which 12 partner institutions from six countries participate.

The drug OSTEOGROW is the first innovative drug in independent Croatia and the second after the very successful Sumamed, which is entirely the product of Croatian scientists. A little blood, a little bone protein and here is a medicine for bone regeneration and healing! The Croatian sensation of world scale in pharmaceuticals is called OSTEOGROW, and the results of the clinical trials conducted so far say that the first drug created in the Croatian state could become an indispensable aid to patients with bone healing problems and those who need to replace a missing part of the bone already in two to three years.